BE2015C070I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C070I2
BE2015C070I2 BE2015C070C BE2015C070C BE2015C070I2 BE 2015C070 I2 BE2015C070 I2 BE 2015C070I2 BE 2015C070 C BE2015C070 C BE 2015C070C BE 2015C070 C BE2015C070 C BE 2015C070C BE 2015C070 I2 BE2015C070 I2 BE 2015C070I2
Authority
BE
Belgium
Application number
BE2015C070C
Other languages
Dutch (nl)
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of BE2015C070I2 publication Critical patent/BE2015C070I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BE2015C070C 2003-11-12 2015-12-09 BE2015C070I2 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51921103P 2003-11-12 2003-11-12
EP04810619A EP1687329B8 (en) 2003-11-12 2004-11-10 Optimized expression of hpv 58 l1 in yeast

Publications (1)

Publication Number Publication Date
BE2015C070I2 true BE2015C070I2 (zh) 2023-12-18

Family

ID=34590374

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C070C BE2015C070I2 (zh) 2003-11-12 2015-12-09

Country Status (32)

Country Link
US (2) US7498036B2 (zh)
EP (1) EP1687329B8 (zh)
JP (2) JP4912885B2 (zh)
KR (1) KR101170654B1 (zh)
CN (1) CN1942583B (zh)
AR (1) AR046835A1 (zh)
AT (1) ATE452977T1 (zh)
AU (1) AU2004290032B2 (zh)
BE (1) BE2015C070I2 (zh)
BR (1) BRPI0416393B1 (zh)
CA (1) CA2543928C (zh)
CY (2) CY1113875T1 (zh)
DE (1) DE602004024821D1 (zh)
DK (1) DK1687329T3 (zh)
ES (1) ES2340287T3 (zh)
FR (1) FR15C0081I2 (zh)
HU (1) HUS1500064I1 (zh)
IL (1) IL175353A (zh)
IS (1) IS2741B (zh)
LT (1) LTC1687329I2 (zh)
LU (1) LU92901I2 (zh)
MY (1) MY139500A (zh)
NL (1) NL300775I2 (zh)
NO (2) NO340633B1 (zh)
NZ (1) NZ546697A (zh)
PL (1) PL1687329T3 (zh)
PT (1) PT1687329E (zh)
RU (1) RU2370538C2 (zh)
SI (1) SI1687329T1 (zh)
TW (1) TWI332988B (zh)
WO (1) WO2005047315A2 (zh)
ZA (1) ZA200603106B (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US8206950B2 (en) 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
EP1730175B1 (en) * 2004-03-24 2010-04-28 Merck Sharp & Dohme Corp. Optimized expression of hpv 52 l1 in yeast
US20070243587A1 (en) * 2006-04-14 2007-10-18 Healthbanks Biotech Co., Ltd. Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
CN101148661B (zh) * 2006-09-18 2013-01-02 中国医学科学院基础医学研究所 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
EP2129394B1 (en) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
US9428555B2 (en) 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
EP2154149B1 (en) * 2007-05-29 2019-07-10 Xiamen University A truncated l1 protein of human papillomavirus 6
CN101113417B (zh) * 2007-06-22 2011-04-27 山东大学 Hpv基因酵母体外翻译系统的建立
CN101200696B (zh) * 2007-11-14 2011-07-20 山东大学 人乳头瘤病毒的酵母增殖模型及建立方法与应用
EP2223933B1 (en) * 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein l1 of human papilloma viruses
KR20090073987A (ko) * 2007-12-31 2009-07-03 정운원 인간유두종바이러스 유전자형 검사를 위한 프라이머, 프로브 및 이를 포함하는 ｄｎａ칩, 이의 검사 방법 및 검사 키트
CN106377767A (zh) * 2008-05-26 2017-02-08 卡迪拉保健有限公司 麻疹‑人乳头瘤组合疫苗
US9335868B2 (en) * 2008-07-31 2016-05-10 Apple Inc. Capacitive sensor behind black mask
AU2011258501B2 (en) 2010-05-25 2016-07-07 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN101857870B (zh) * 2010-06-12 2012-09-05 上海泽润生物科技有限公司 Hpv58 l1基因及载体、菌株和表达方法
CN102336822B (zh) * 2010-07-16 2015-10-14 厦门大学 截短的人乳头瘤病毒58型l1蛋白
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
BR112013032338B1 (pt) * 2011-06-15 2021-04-20 Posvax Co., Ltd método para melhorar o rendimento de produção para proteína l1 do papilomavírus humano
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
JP6423987B2 (ja) 2012-06-07 2018-11-14 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 制御された遺伝子発現方法
CN103992395B (zh) * 2013-02-18 2018-07-27 北京康乐卫士生物技术股份有限公司 重组hpv-58型l1的vlp疫苗及其制备方法
CN104120088B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CN104164373B (zh) * 2013-05-17 2019-04-02 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv68l1蛋白的方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
MA40624A (fr) * 2014-09-11 2016-03-17 Cadila Healthcare Ltd Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
CN117187263A (zh) * 2015-03-30 2023-12-08 上海泽润生物科技有限公司 重组人乳头瘤病毒33亚型蛋白表达
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
US10940194B2 (en) * 2015-12-04 2021-03-09 Xiamen University Mutant of L1 protein of human papillomavirus type 58
WO2021163002A1 (en) 2020-02-14 2021-08-19 Merck Sharp & Dohme Corp. Hpv vaccine
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
US20230048144A1 (en) 2021-08-06 2023-02-16 Merck Sharp & Dohme Llc Hpv vaccine
WO2023023152A1 (en) 2021-08-19 2023-02-23 Merck Sharp & Dohme Llc Thermostable lipid nanoparticle and methods of use thereof
CN117054647A (zh) * 2023-07-17 2023-11-14 广东省一鼎生物技术有限公司 一种检测HPV IgG抗体试剂盒及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
ES2274566T3 (es) 1997-02-07 2007-05-16 MERCK & CO., INC. Genes gag del vih sinteticos.
WO1999002694A1 (en) 1997-07-09 1999-01-21 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
JP4563582B2 (ja) 1998-08-14 2010-10-13 メルク・シャープ・エンド・ドーム・コーポレイション ヒトパピローマウイルスのウイルス様粒子を使用するタンパク質送達系
CN1354787A (zh) * 1998-08-14 2002-06-19 麦克公司 纯化人乳头瘤病毒样颗粒的方法
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
CA2381991A1 (en) 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic human papillomavirus genes
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
CN1262665C (zh) 2000-07-21 2006-07-05 葛兰素集团有限公司 经过密码子最优化的乳头状瘤病毒序列
AU2003213065A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Novel insect cell line
MXPA05010285A (es) 2003-03-24 2005-11-17 Merck & Co Inc Expresion optimizada de hpv 31 l1 en levadura.
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Also Published As

Publication number Publication date
US20070036824A1 (en) 2007-02-15
BRPI0416393A (pt) 2007-04-03
LTC1687329I2 (lt) 2017-05-10
KR20060122852A (ko) 2006-11-30
FR15C0081I2 (fr) 2016-11-25
ES2340287T3 (es) 2010-06-01
ZA200603106B (en) 2007-09-26
AU2004290032A1 (en) 2005-05-26
PL1687329T3 (pl) 2010-06-30
EP1687329A2 (en) 2006-08-09
NZ546697A (en) 2009-05-31
CA2543928C (en) 2011-04-05
EP1687329B8 (en) 2010-03-17
NO2017058I1 (no) 2017-11-10
RU2006120402A (ru) 2007-12-27
NL300775I1 (zh) 2015-12-29
EP1687329B1 (en) 2009-12-23
US7498036B2 (en) 2009-03-03
KR101170654B1 (ko) 2012-08-03
MY139500A (en) 2009-10-30
NO340633B1 (no) 2017-05-15
IL175353A (en) 2010-11-30
JP2012095652A (ja) 2012-05-24
IS2741B (is) 2011-06-15
CY1113875T1 (el) 2016-06-22
AR046835A1 (es) 2005-12-28
CA2543928A1 (en) 2005-05-26
BRPI0416393B1 (pt) 2021-06-29
US7976848B2 (en) 2011-07-12
NL300775I2 (zh) 2015-12-29
JP4912885B2 (ja) 2012-04-11
US20100272749A1 (en) 2010-10-28
TWI332988B (en) 2010-11-11
IS8425A (is) 2006-04-21
JP5616879B2 (ja) 2014-10-29
SI1687329T1 (sl) 2010-03-31
DE602004024821D1 (de) 2010-02-04
AU2004290032B2 (en) 2009-02-05
DK1687329T3 (da) 2010-04-12
FR15C0081I1 (fr) 2016-08-01
CN1942583B (zh) 2010-10-27
WO2005047315A3 (en) 2006-09-28
IL175353A0 (en) 2006-09-05
CY2015051I2 (el) 2016-06-22
HUS1500064I1 (hu) 2016-02-29
PT1687329E (pt) 2010-02-26
NO20062674L (no) 2006-06-09
CY2015051I1 (el) 2016-06-22
LU92901I2 (fr) 2016-03-08
WO2005047315A2 (en) 2005-05-26
CN1942583A (zh) 2007-04-04
RU2370538C2 (ru) 2009-10-20
TW200519203A (en) 2005-06-16
JP2008500019A (ja) 2008-01-10
ATE452977T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
BE2015C070I2 (zh)
BE2014C055I2 (zh)
BE2014C027I2 (zh)
JP2004026150A5 (zh)
JP2004187283A5 (zh)
BE2015C005I2 (zh)
JP2003338636A5 (zh)
JP2004205512A5 (zh)
JP2004183662A5 (zh)
JP2004136639A5 (zh)
JP2003246306A5 (zh)
JP2004213453A5 (zh)
JP2003278614A5 (zh)
JP2003333427A5 (zh)
JP2004221781A5 (zh)
JP2004215632A5 (zh)
JP2004222999A5 (zh)
JP2003334244A5 (zh)
AU2002321535A1 (zh)
AU2002327736A1 (zh)
AU2002316511A1 (zh)
AU2002318342A1 (zh)
AU2002353888A1 (zh)
AU2002322913A1 (zh)
AU2002324323A1 (zh)